BIOMARKERS FOR DIABETES

摘要

The present invention provides a method for assessing the presence and risk of developing type 2 diabetes, cancer of all sites, or cardiovascular disease in a subject by detecting sequence variation in one or more genes such as carboxypeptidase E (CPE) and insulin degradation enzyme (IDE). A kit, array, and device useful for such a method are also provided. In addition, the present invention provides a method for treating type 2 diabetes, cancer of all sites, or cardiovascular disease in patients who have been tested and shown to have the pertinent genetic variations.

主权项

1. A method for assessing the presence or risk of type 2 diabetes, cancer, or cardiovascular disease in a subject, comprising the steps of:
(a) performing an assay that determines nucleotide sequence of at least a portion of genomic sequence of carboxypeptidase E (CPE) present in a biological sample taken from the subject, and (b) comparing the sequence determined in step (a) with a corresponding standard sequence of CPE, wherein a variation in the sequence determined in step (a) when compared with the standard sequence indicates that the subject has or is at risk of developing type 2 diabetes, cancer, or cardiovascular disease.